


This article was downloaded by: [University of Waterloo]

On: 04 September 2013, At: 03:33

Publisher: Taylor & Francis

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Nucleosides and Nucleotides

Publication details, including instructions for authors and subscription information:

<http://www.tandfonline.com/loi/Incn19>

Derivatives of L-Adenosine and L-Guanosine as Substrates for Human Deoxycytidine Kinase

G. Gaubert ^a, G. Gosselin ^a, J-L. Imbach ^a, S. Eriksson ^b & G. Maury ^a

^a Laboratoire de Chimie Bioorganique, UMR 5625 du CNRS, Université Montpellier II, Place E. Bataillon, 34095, Montpellier Cedex 5, France

^b Swedish University of Agricultural Sciences, Department of Veterinary Medical Chemistry, the Biomedical Center, Box 575, S-75123, Uppsala, Sweden

Published online: 04 Oct 2006.

To cite this article: G. Gaubert, G. Gosselin, J-L. Imbach, S. Eriksson & G. Maury (1999) Derivatives of L-Adenosine and L-Guanosine as Substrates for Human Deoxycytidine Kinase, *Nucleosides and Nucleotides*, 18:4-5, 857-860, DOI: [10.1080/15257779908041581](https://doi.org/10.1080/15257779908041581)

To link to this article: <http://dx.doi.org/10.1080/15257779908041581>

PLEASE SCROLL DOWN FOR ARTICLE

Taylor & Francis makes every effort to ensure the accuracy of all the information (the "Content") contained in the publications on our platform. However, Taylor & Francis, our agents, and our licensors make no representations or warranties whatsoever as to the accuracy, completeness, or suitability for any purpose of the Content. Any opinions and views expressed in this publication are the opinions and views of the authors, and are not the views of or endorsed by Taylor & Francis. The accuracy of the Content should not be relied upon and should be independently verified with primary sources of information. Taylor and Francis shall not be liable for any losses, actions, claims, proceedings, demands, costs, expenses, damages, and other liabilities whatsoever or howsoever caused arising directly or indirectly in connection with, in relation to or arising out of the use of the Content.

This article may be used for research, teaching, and private study purposes. Any substantial or systematic reproduction, redistribution, reselling, loan, sub-licensing, systematic supply, or distribution in any form to anyone is expressly forbidden. Terms &

DERIVATIVES OF L-ADENOSINE AND L-GUANOSINE AS SUBSTRATES FOR HUMAN DEOXYCYTIDINE KINASE

G. Gaubert¹, G. Gosselin¹, J.-L. Imbach¹, S. Eriksson² and G. Maury^{1*}.

¹Laboratoire de Chimie Bioorganique, UMR 5625 du CNRS, Université Montpellier II, Place E. Bataillon, 34095 Montpellier Cedex 5, France.

² Swedish University of Agricultural Sciences, Department of Veterinary Medical Chemistry, the Biomedical Center, Box 575, S-75123 Uppsala, Sweden.

ABSTRACT: A series of analogues of L-adenosine and of L-guanosine, including β -L-dA, β -L-Ado, β -L-araA, and β -L-dG, have been shown to be substrates of human deoxycytidine kinase thus demonstrating the complete lack of enantioselectivity of this enzyme.

The recent discovery of the antiviral or anticancer properties of some L-nucleoside analogues has prompted a considerable interest for these compounds. Indeed, they present same order activities as the corresponding D-enantiomers and also have lower short-term cytotoxicities^{1,2}. To be active, L-nucleosides have to be enzymatically converted to the corresponding 5'-triphosphate derivatives which are the entities able to inhibit viral DNA polymerases. Consequently, the activity of a L-nucleoside analogue depends primarily on the enantioselectivity of the activation enzymes (kinases), of the deactivation enzymes (deaminases, phosphorylases) and of the viral or cellular polymerases. We are currently studying the correlation between the antiviral activities of L-nucleoside analogues and the properties of these enzymes, especially the nucleoside kinases which catalyze the first phosphorylation step of the nucleosides. This step is often considered as the most critical in the transformation of the nucleoside to the 5'-triphosphate. Thus, the anti-HIV or anti-HBV activities of several analogues of L-

cytidine have been explained by the considerably relaxed enantioselectivity of human deoxycytidine kinase (dCK) for these compounds^{3,4}. Owing to the fact that, not only β -D-2'-deoxycytidine but also β -D-2'-deoxyadenosine and β -D-2'-deoxyguanosine are substrates of dCK⁵, we have examined the properties of several derivatives of β -L-adenosine⁶ or β -L-guanosine with respect to the human enzyme and we report here some of the results of this study.

MATERIALS AND METHODS

Recombinant human dCK was purified using the human dCK cDNA sequence cloned into the pET19b and pET9d vector⁷. Both types of preparations contained a histidine tag sequence and were more than 90% pure with very similar properties.

The derivatives of L-adenosine or L-guanosine were stereospecifically synthesized according to previously published procedures or using new methods from commercially available L-sugars. The details of synthesis as well as the results of their antiviral evaluation will be reported elsewhere.

In kinetic studies, the reaction medium contained 50 mM Tris HCl pH 7.5, 5 mM ATP, 5 mM MgCl₂, 1 mM dithiothreitol, appropriate amounts of substrate and the enzyme (2.4 to 160 μ g/ml, depending on the substrate). Analyses of the reaction mixture were performed by HPLC on a Hypersil C-18 3 μ m column under the following conditions: 5 min of isocratic elution using eluent A (phosphate buffer 50 mM pH 5.9) followed by 80 min linear gradient from eluent A to eluent B (phosphate buffer 50 mM pH 5.9 and 40% acetonitrile) with a flow rate of 1 mL.min⁻¹. The identifications of the products were achieved through coinjection of authentic samples or from the UV spectra of the eluted compounds. The kinetic curves were determined at 37°C by at least three measurements of substrate transformation as a function of time. The apparent kinetic parameters were obtained using the Grafit program (Erithacus Software, 1992) according to the Lineweaver-Burk method.

RESULTS AND DISCUSSION

The kinetic parameters of the studied nucleoside analogues are presented in Table 1.

TABLE 1. Substrate properties of the studied nucleoside analogues vs. dCK

Compound	K _m (μ M)	V _m (μ mol/min/mg)	Compound	K _m (μ M)	V _m (μ mol/min/mg)
β -D-dA	230	0.90	β -L-dA	40	0.20
β -D-Ado	a	a	β -L-Ado	200	0.006
β -D-araA	640	0.098	β -L-araA	820	0.26
β -D-dG	130	0.47	β -L-dG	220	0.16
β -D-3'dG	a	a	β -L-3'dG	1600	0.003

^aReaction too slow to allow the determination of kinetic parameters.

It is remarkable that the most efficient substrate studied (as calculated from K_m/V_m values) is an unnatural enantiomer, namely β -L-dA. The D-enantiomers β -D-dA and β -D-dG were slightly less efficient and β -L-dG was 5 times less effective than its D-enantiomer. Both enantiomers of β -araA were average substrates of the enzyme compared to β -D-dA. Finally, the 2',3'-dideoxynucleosides in the guanosine and in the adenosine series⁶, were poor substrates of human dCK regardless of enantiomerism. Our results demonstrated that the lack of enantioselectivity of dCK for cytidine derivatives⁴ could be extended to the adenosine or guanosine series, thus increasing the field of potentially active L-nucleoside analogues in antiviral therapy.

REFERENCES

1. Furman, P.A.; Wilson, J.E.; Reardon, J.E.; Painter, G.R. *Antiviral Chem. Chemother.* **1995**, *6*, 345.
2. Lin, T-S.; Luo, M.-Z.; Liu, M.-C.; Pai, S.B.; Dutschman, G.E.; Cheng Y.-C. *J. Med. Chem.* **1994**, *37*, 798.
3. Shewach, D.S.; Liotta, D.C.; Schinazi, R.F. *Biochem Pharmacol.* **1993**, *45*, 1540.
4. Shafiee, M.; Griffon, J.-F.; Gosselin, G.; Cambi, A.; Vincenzetti, S.; Vita, A.; Eriksson, S.; Imbach, J.-L.; Maury, G. *Biochem. Pharmacol.*, In press.
5. Arner, S.J.; Eriksson, S. *Pharmac Ter.* **1995**, *67*, 155.

6. Pelicano, H.; Pierra, C.; Eriksson, S.; Gosselin, G.; Imbach, J.-L.; Maury, G. *J. Med. Chem.* **1997**, *40*, 3969.

7. Usova, E.; Eriksson, S. *Eur. J. Biochem.* **1997**, *248*, 762.